Advanced search
1 file | 311.99 KB Add to list

Patterns of transmitted HIV drug resistance in Europe vary by risk group

(2014) PLOS ONE. 9(4).
Author
Organization
Abstract
Background: In Europe, a continuous programme (SPREAD) has been in place for ten years to study transmission of drug resistant HIV. We analysed time trends of transmitted drug resistance mutations (TDRM) in relation to the risk behaviour reported. Methods: HIV-1 patients newly diagnosed in 27 countries from 2002 through 2007 were included. Inclusion was representative for risk group and geographical distribution in the participating countries in Europe. Trends over time were calculated by logistic regression. Results: From the 4317 patients included, the majority was men-having-sex-with-men -MSM (2084, 48%), followed by heterosexuals (1501, 35%) and injection drug users (IDU) (355, 8%). MSM were more often from Western Europe origin, infected with subtype B virus, and recently infected (<1 year) (p<0.001). The prevalence of TDRM was highest in MSM (prevalence of 11.1%), followed by heterosexuals (6.6%) and IDU (5.1%, p<0.001). TDRM was predominantly ascribed to nucleoside reverse transcriptase inhibitors (NRTI) with a prevalence of 6.6% in MSM, 3.3% in heterosexuals and 2.0% in IDU (p = 0.001). A significant increase in resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) and a decrease in resistance to protease inhibitors was observed in MSM (p = 0.008 and p = 0.006, respectively), but not in heterosexual patients (p = 0.68 and p = 0.14, respectively). Conclusions: MSM showed to have significantly higher TDRM prevalence compared to heterosexuals and IDU. The increasing NNRTI resistance in MSM is likely to negatively influence the therapy response of first-line therapy, as most include NNRTI drugs.
Keywords
INFECTION, MUTATIONS, USERS, PREVALENCE, EPIDEMIOLOGY, INDIVIDUALS, TRANSMISSION, ACTIVE ANTIRETROVIRAL THERAPY, APPEARANCE, POPULATIONS

Downloads

  • 22.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 311.99 KB

Citation

Please use this url to cite or link to this publication:

MLA
Frentz, Dineke et al. “Patterns of Transmitted HIV Drug Resistance in Europe Vary by Risk Group.” PLOS ONE 9.4 (2014): n. pag. Print.
APA
Frentz, D., van de Vijver, D., Abecasis, A., Albert, J., Hamouda, O., Jørgensen, L., Kücherer, C., et al. (2014). Patterns of transmitted HIV drug resistance in Europe vary by risk group. PLOS ONE, 9(4).
Chicago author-date
Frentz, Dineke, David van de Vijver, Ana Abecasis, Jan Albert, Osamah Hamouda, Louise Jørgensen, Claudia Kücherer, et al. 2014. “Patterns of Transmitted HIV Drug Resistance in Europe Vary by Risk Group.” Plos One 9 (4).
Chicago author-date (all authors)
Frentz, Dineke, David van de Vijver, Ana Abecasis, Jan Albert, Osamah Hamouda, Louise Jørgensen, Claudia Kücherer, Daniel Struck, Jean-Claude Schmit, Jurgen Vercauteren, Birgitta Åsjö, Claudia Balotta, Colm Bergin, Danail Beshkov, Ricardo Camacho, Bonaventura Clotet, Algirdas Griskevicius, Zehava Grossman, Andrzej Horban, Tatjana Kolupajeva, Klaus Korn, Leondios Kostrikis, Kirsi Liitsola Marek Linka, Claus Nielsen, Dan Otelea, Dimitrios Paraskevis, Roger Paredes, Mario Poljak, Elisabeth Puchhammer-Stöckl, Anders Sönnerborg, Danica Stanekova, Maja Stanojevic, Anne-Mieke Vandamme, Charles Boucher, Annemarie Wensing, on behalf of the SPREAD Programme, and Linos Vandekerckhove. 2014. “Patterns of Transmitted HIV Drug Resistance in Europe Vary by Risk Group.” Plos One 9 (4).
Vancouver
1.
Frentz D, van de Vijver D, Abecasis A, Albert J, Hamouda O, Jørgensen L, et al. Patterns of transmitted HIV drug resistance in Europe vary by risk group. PLOS ONE. 2014;9(4).
IEEE
[1]
D. Frentz et al., “Patterns of transmitted HIV drug resistance in Europe vary by risk group,” PLOS ONE, vol. 9, no. 4, 2014.
@article{5913127,
  abstract     = {{Background: In Europe, a continuous programme (SPREAD) has been in place for ten years to study transmission of drug resistant HIV. We analysed time trends of transmitted drug resistance mutations (TDRM) in relation to the risk behaviour reported. 
Methods: HIV-1 patients newly diagnosed in 27 countries from 2002 through 2007 were included. Inclusion was representative for risk group and geographical distribution in the participating countries in Europe. Trends over time were calculated by logistic regression. 
Results: From the 4317 patients included, the majority was men-having-sex-with-men -MSM (2084, 48%), followed by heterosexuals (1501, 35%) and injection drug users (IDU) (355, 8%). MSM were more often from Western Europe origin, infected with subtype B virus, and recently infected (<1 year) (p<0.001). The prevalence of TDRM was highest in MSM (prevalence of 11.1%), followed by heterosexuals (6.6%) and IDU (5.1%, p<0.001). TDRM was predominantly ascribed to nucleoside reverse transcriptase inhibitors (NRTI) with a prevalence of 6.6% in MSM, 3.3% in heterosexuals and 2.0% in IDU (p = 0.001). A significant increase in resistance to non-nucleoside reverse transcriptase inhibitors (NNRTIs) and a decrease in resistance to protease inhibitors was observed in MSM (p = 0.008 and p = 0.006, respectively), but not in heterosexual patients (p = 0.68 and p = 0.14, respectively). 
Conclusions: MSM showed to have significantly higher TDRM prevalence compared to heterosexuals and IDU. The increasing NNRTI resistance in MSM is likely to negatively influence the therapy response of first-line therapy, as most include NNRTI drugs.}},
  articleno    = {{e94495}},
  author       = {{Frentz, Dineke and van de Vijver, David and Abecasis, Ana and Albert, Jan and Hamouda, Osamah and Jørgensen, Louise and Kücherer, Claudia and Struck, Daniel and Schmit, Jean-Claude and Vercauteren, Jurgen and Åsjö, Birgitta and Balotta, Claudia and Bergin, Colm and Beshkov, Danail and Camacho, Ricardo and Clotet, Bonaventura and Griskevicius, Algirdas and Grossman, Zehava and Horban, Andrzej and Kolupajeva, Tatjana and Korn, Klaus and Kostrikis, Leondios and Linka, Kirsi Liitsola Marek and Nielsen, Claus and Otelea, Dan and Paraskevis, Dimitrios and Paredes, Roger and Poljak, Mario and Puchhammer-Stöckl, Elisabeth and Sönnerborg, Anders and Stanekova, Danica and Stanojevic, Maja and Vandamme, Anne-Mieke and Boucher, Charles and Wensing, Annemarie and SPREAD Programme, on behalf of the and Vandekerckhove, Linos}},
  issn         = {{1932-6203}},
  journal      = {{PLOS ONE}},
  keywords     = {{INFECTION,MUTATIONS,USERS,PREVALENCE,EPIDEMIOLOGY,INDIVIDUALS,TRANSMISSION,ACTIVE ANTIRETROVIRAL THERAPY,APPEARANCE,POPULATIONS}},
  language     = {{eng}},
  number       = {{4}},
  pages        = {{7}},
  title        = {{Patterns of transmitted HIV drug resistance in Europe vary by risk group}},
  url          = {{http://dx.doi.org/10.1371/journal.pone.0094495}},
  volume       = {{9}},
  year         = {{2014}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: